Skip to main content
Skip to main content
Normal View Dyslexic View

Aspirin for cancer prevention in individuals with Lynch syndrome: first results from the CaPP3 multicentre, randomised, double-blind, non-inferiority trial

BJSA
BJS Academy
0000-0000
BJS Foundation Limited
London, UK
Burn J, Borthwick GM, Elliott F, Macrae F, Ong KR, Kraus AC et al.
Lancet Gastroenterol Hepatol 2026; 11: 760-774.
Among 1 866 individuals with Lynch syndrome, 100 mg aspirin was non-inferior to 600 mg in the intention-to-treat analysis (hazard ratio for time to first Lynch syndrome cancer 0.97, 95 per cent confidence interval 0.67 to 1.42), but this was not reproduced in the per-protocol analysis. Non-inferiority was not shown for 300 mg. Serious bleeding occurred in none on 100 mg versus 1.5 per cent on 600 mg.
Comment: Non-inferiority could not be formally concluded for lower doses of daily aspirin (100mg, 300mg) when compared to 600mg.
Comment by Jeongyoon (Jenny) Moon, MD

Related articles


25 September 2024

Pyridostigmine to reduce the duration of postoperative Ileus after colorectal surgery (PyRICo-RCT): randomized clinical trial.

Traeger L, Bedrikovetski S, Fitzsimmons T, Nguyen T-M, Moore JW, Lewis M et al.

7 August 2024
30 August 2024
Copied!